~~<i id='2A2D0D5D0C'><strike id='2A2D0D5D0C'><tt id='2A2D0D5D0C'><pre id='2A2D0D5D0C'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：Wikipedia 2025-10-06 17:36:53 Page View：7459

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Charles Manson follower Leslie Van Houten released from prison after 53 years
Next article： Duchenne breakthrough therapy leaves behind pioneering families

focus

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Beach reads and more: STAT's 2023 summer book list

AlexHogan/STATWithsummerinfullswing,it’sagreattimetotuckintoanewbookorpodcast.Whetheryou’relookingfo

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

ALS treatment from Biogen, Ionis fails in study

RubyWallauforSTATAplantousenewgenetictechniquestotreatnon-geneticformsofALSfailedinanearlystudy,Ioni